Long-Awaited TAILORx Results 'Will Impact Your Practice'

Hi. It's Dr Kathy Miller from Indiana University. I want to give you a quick preview of what you should be looking for in the breast cancer abstracts at the American Society of Clinical Oncology (ASCO) annual meeting this year. Do not miss the Plenary Session. We have been waiting for almost 7 years for the results of the TAILORx trial. We will wait no longer.

It was about 10 years ago that we first learned about and grew comfortable with the Oncotype DX® Breast Recurrence Score assay to identify which of our patients with node-negative, ER-positive tumors really needed chemotherapy.^[1] Those with a low score really did not get any benefit. Conversely, those with a high score had huge benefit—much more than we had ever seen with chemotherapy in an ER-positive setting.

For all its power, Oncotype DX had an Achilles' heel, if you will. We had uncertainty about the benefits of chemotherapy in patients with an intermediate risk score. The point estimate for that group as a whole suggested that there was really not a benefit from chemo, but the confidence intervals included that same 2%-4% benefit that we might get from lumping everybody together. Thus, this was purpose of the TAILORx trial.